USIL Therapeutics is a Luxembourg-based biotech developing medicines to protect people from the effects of ionizing radiation. Our lead candidate, UT-241, is designed for intramuscular delivery via an autoinjector and aims to mitigate acute radiation syndrome by supporting DNA repair and reducing oxidative stress. We are building on preclinical efficacy data and existing human safety data for an intravenous formulation. Supported by €5.5 million in non-dilutive funding, we are advancing development for potential use by armed forces, emergency responders and nuclear-industry personnel. We are raising a seed round to fund the next stages of validation and regulatory development.
